Drug intelligence / Profile preview

mPO-6

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Intravenous

Overview

mPO-6 is a novel therapeutic agent comprising a CD123 antagonistic peptide (PO-6) encapsulated within nanomicelles. It is being developed for the targeted treatment of refractory acute myeloid leukemia (AML). The drug works by binding to CD123-positive AML cells and interfering with the CD123/IL-3 signaling axis, which subsequently leads to the downregulation of STAT5 and PI3K/AKT phosphorylation and the inhibition of activated NF-κB. This antagonistic action results in a significant reduction of AML cell infiltration.

Other names: PO-6 loaded in nanomicellesPO6 loaded in nanomicellesPO 6 loaded in nanomicelles

Targets

IL3RA (Interleukin 3 Receptor)

Beyond the preview

Go deeper on mPO-6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mPO-6.

Explore the full profile